LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Search

Biogen Inc

Cerrado

Sector Salud

200.08 -0.66

Resumen

Variación precio

24h

Actual

Mínimo

199.17

Máximo

200.85

Métricas clave

By Trading Economics

Ingresos

190M

584M

Ventas

180M

2.5B

P/B

Media del Sector

28.98

103.001

BPA

5.28

Margen de beneficio

23.628

Empleados

7,570

EBITDA

237M

919M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+37 upside

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

122M

30B

Apertura anterior

200.74

Cierre anterior

200.08

Noticias sobre sentimiento de mercado

By Acuity

34%

66%

64 / 365 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Biogen Inc Gráfico

Noticias Relacionadas

6 sept 2024, 11:00 UTC

Principales Noticias

Pandemic Darling Moderna Needs a Reality Check -- Heard on the Street -- WSJ

29 may 2024, 15:56 UTC

Ganancias
Adquisiciones, fusiones, absorciones

The Moderna Selloff Gains Steam. An Analyst Has a Few Theories Why. -- Barrons.com

4 oct 2023, 17:55 UTC

Adquisiciones, fusiones, absorciones

Is Eli Lilly Stock A Buy Following Its $1.4 Billion Point Biopharma Takeover In Cancer Treatment? -- IBD

Comparación entre iguales

Cambio de precio

Biogen Inc Esperado

Precio Objetivo

By TipRanks

37% repunte

Estimación a 12 meses

Media 275.11 USD  37%

Máximo 342 USD

Mínimo 190 USD

De acuerdo con 19 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Biogen Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

19 ratings

16

Comprar

3

Mantener

0

Vender

Puntuación técnica

By Trading Central

198.19 / 204.86Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

64 / 365 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Biogen Inc

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company's marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; GAZYVA indicated for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS), and other anti-CD20 therapies. The Company's pipeline includes BIIB074; BAN2401; BIIB061; BIIB067, BIIB124, BIIB074, BIIB118 and TMS-007.